Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
28 June 2018
E-002569/2018
Answer given by Mr Andriukaitis on behalf of the Commission

The Impact Assessment(1) on the Commission’s proposal(2) on Health Technology Assessment (HTA) showed that there are important differences in the processes and definitions of health technology assessments in the Member States. Therefore, it is not appropriate to give one figure for the number or for the cost of HTAs undertaken in the EU. Nonetheless, it can be concluded that the cost of producing a single-technology HTA by Member States authorities ranged from EUR 4 000 to EUR 135 000.

1. The number of assessments carried out by national HTA bodies range from 5 HTAs per year to up to 390 HTAs per year. However, as mentioned above, they vary greatly in methodology and therefore it would not be appropriate/ adequate to provide a consolidated annual figure.

2. The costs for joint health technology assessments were modelled on the experience of the EUnetHTA Join Action,(3) where a joint assessment on relative effectiveness assessment (REA) for pharmaceuticals has a cost of EUR 117 000. However, these are the costs in the framework of the pilot exercises and once conducted routinely the unit cost is expected to markedly decrease. In fact, a study showed that the cost savings related to the joint REA are estimated at EUR 1 560 000 to EUR 2 670 000 per year for HTA bodies(4). This is in line with the results of the focus group meeting with public administrations carried out in the context of the study. The participants agreed that a stronger EU cooperation would lead to a cost decrease per joint output (once the system is well established and running). The saving will of course depend on the number of joint assessments carried out.

(1)https://ec.europa.eu/health/sites/health/files/technology_assessment/docs/2018_ia_final_en.pdf
(2)https://ec.europa.eu/health/sites/health/files/technology_assessment/docs/com2018_51final_en.pdf
(3)https://www.eunethta.eu/
(4)https://ec.europa.eu/health/sites/health/files/technology_assessment/docs/2018_ia_policyoptions_en.pdf

Last updated: 29 June 2018Legal notice